Pharma Sector

EBITDA increased by 10.2% to ₹391.1 Crore in the first quarter of this fiscal year, up from ₹355 Crore the previous year.

According to a stock exchange filing, the Company has received an Establishment Inspection Report (EIR) with Voluntary Action Indicated.

The company's first-quarter earnings before interest, taxes, depreciation, and amortisation (EBITDA) were ₹622 Crore.

The EBITDA margin was 17.95% in the reporting quarter, compared to 18.2% in the same time the previous fiscal year.

In May, Mankind's board approved an equity fund raising of ₹7,500 Crore and raised borrowing restrictions to ₹12,500 Crore.

The company announced that its India business grew by 10% year on year in the June quarter, with sales rising to ₹1,635 Crore from ₹1,426 Crore in Q1 FY24.

Following this development, company’s counter slipped nearly 3% to an intraday low of ₹1,150.05 per piece on NSE.

The record date for the share buyback has been set as July 30, 2024. Promoters will also participate in the share buyback.

The company stated that its production facility in Bharuch successfully completed its USFDA inspection with zero 483 findings.

The Delhi-based startup has signed in-licensing arrangements with Novartis for the heart failure treatment Neptaz.